Abiomed shares overvalued, says Northland Securities Northland believes Abiomed utilization rates for Impella are going down on both the ImpellaCP and Impella 2.5. The firm said Abiomed's story is now dependent on new site add-ons where utilization rates haven moved and sees risk to shares. The firm rates Abiomed an Underperform with a $14 price target.
Abiomed price target raised to $72 from $60 at Leerink Leerink raised its price target for Abiomed shares to $72 saying it believes recent adoption momentum is sustainable as the company continues to penetrate the emergent and high risk percutaneous coronary intervention patient population. It reiterates an Outperform rating on the stock.